TOP TEN perturbations for 39825_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39825_at
Selected probe(set): 210010_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39825_at (210010_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
uterine/pelvic pathology study 2 (late se MCP) / uterine/pelvic pathology study 2 (early se MCP)
Relative Expression (log2-ratio):-2.7840424Number of Samples:2 / 6
| Experimental | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (early se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):2.542429Number of Samples:15 / 2
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.5175934Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (tularensis Schu S4) |
| Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
PBDE study 1 (2-OH-BDE85) / vehicle (DMSO) treated H295R cell sample
Relative Expression (log2-ratio):-2.45689Number of Samples:3 / 3
| Experimental | PBDE study 1 (2-OH-BDE85) |
| H295R adrenocortical carcinoma cells treated for 24 hours with 10µM of a hydroxylated form of the brominated flame retardant 2-OH-BDE85 dissolved in 0.1% dimethyl sulfoxide (DMSO). ATC code:--- | |
| Control | vehicle (DMSO) treated H295R cell sample |
| H295R adrenocortical carcinoma cells grown for 24 hours with 0.1% dimethyl sulfoxide (DMSO). |
Sjogren's syndrome study 1 (advanced) / normal minor salivary gland tissue
Relative Expression (log2-ratio):-2.2590294Number of Samples:2 / 4
| Experimental | Sjogren's syndrome study 1 (advanced) |
| Whole minor salivary gland samples of patients with advanced Sjogren's syndrome. | |
| Control | normal minor salivary gland tissue |
| Whole minor salivary gland samples from non-Sjogren's syndrome control subjects. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.2449903Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
uterine/pelvic pathology study 2 (mid-se MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):2.2381191Number of Samples:14 / 2
| Experimental | uterine/pelvic pathology study 2 (mid-se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the mid-secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.1864758Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS27a) |
| CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-2.169301Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tetracycline study 7 (2000uM) / vehicle (DMSO) treated HepG2 sample
Relative Expression (log2-ratio):-2.1673374Number of Samples:3 / 21
| Experimental | tetracycline study 7 (2000uM) |
| HepG2 cells treated with compound: tetracycline (2000uM; CAS no.:60-54-8) for 24 hours. Tetracycline is hepatotoxic and may cause steatosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:, , , , , | |
| Control | vehicle (DMSO) treated HepG2 sample |
| HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours. |